Company news

Scholar Rock Holding Corporation news in 2026

Scholar Rock Holding Corporation's news releases, calls and decks from 2026, newest first.

View company

Scholar Rock to Present at Upcoming Investor Conferences

November 3, 2026

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

October 20, 2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 16, 2026

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

October 8, 2026

Scholar Rock Announces FDA Approval of ISEMBYLD (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

September 14, 2026

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

September 11, 2026

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

September 2, 2026

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

August 21, 2026

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

August 7, 2026

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 6, 2026

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

July 29, 2026

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

July 20, 2026

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

July 16, 2026

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

June 22, 2026

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

May 20, 2026

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 7, 2026

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

April 29, 2026

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

April 16, 2026

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

March 30, 2026

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

March 3, 2026

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

February 10, 2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

Scholar Rock Highlights 2026 Strategic Priorities

January 11, 2026

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026